Compare FSP & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSP | GANX |
|---|---|---|
| Founded | 1981 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.4M | 78.2M |
| IPO Year | 2001 | 2021 |
| Metric | FSP | GANX |
|---|---|---|
| Price | $0.63 | $1.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 552.7K | ★ 707.7K |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | ★ 6.34% | N/A |
| EPS Growth | 15.69 | ★ 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $107,162,000.00 | $55,180.00 |
| Revenue This Year | $17.91 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $1.41 |
| 52 Week High | $1.82 | $4.34 |
| Indicator | FSP | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 55.65 | 47.09 |
| Support Level | $0.58 | $1.66 |
| Resistance Level | $0.70 | $2.12 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 51.01 | 36.73 |
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.